With an average surface of about 2 m 2 , the skin is one of our largest organs. Apart from acting as supportive tissue, its functions range from that of a multisensory, thermoregulative, hormonal and immunocompetent organ to that of a most effective physical and metabolic barrier against exogenous and xenobiotic impacts. In our chemical world, testing for skin toxicity hence is a basic requirement in most toxicological frameworks. It could be seen as sign of the systems efficiency that, unless being a hard-born regulator, most scientists will be familiar with skin toxicity as such but knowledge about the corresponding regulatory framework tends to be limited. Yet, it is necessary to understand the frame set by these regulations in order to make skin toxicity testing fit for the future, particularly as the translation of new approach methodologies and more 3R ( 
| S E T TING THE FR AME
With an average surface of about 2 m 2 , the skin is one of our largest organs. Apart from acting as supportive tissue, its functions range from that of a multisensory, thermoregulative, hormonal and immunocompetent organ to that of a most effective physical and metabolic barrier against exogenous and xenobiotic impacts. In our chemical world, testing for skin toxicity hence is a basic requirement in most toxicological frameworks. It could be seen as sign of the systems efficiency that, unless being a hard-born regulator, most scientists will be familiar with skin toxicity as such but knowledge about the corresponding regulatory framework tends to be limited. Yet, it is necessary to understand the frame set by these regulations in order to make skin toxicity testing fit for the future, particularly as the translation of new approach methodologies and more 3R (Table 1 ) compliant tests into regulatory toxicity testing often still shows considerable lag. [1] Apart from experimental issues such as model complexity, species specificity, reliability and ease of transferability, one reason is that safety tests need to serve an existing regulatory framework rather than to produce scientific knowledge. In consequence, new or alternative tests will have to align with existing regulatory principles, at least to some extent. This is far from trivial as experimental issues are straightforward to address and can usually be overcome. However, subsequently fitting the outcome into a long grown international system of rules and guidelines with the requirement of interdisciplinary consensus and a resulting inherent resistance to too much change then tends to complicate things. This review shall hence approach the implementation of new 3R principles from the regulatory side and summarise where we do stand before elucidating where we might want to go and how to get there.
In Europe, the main regulations for chemical safety testing com- Table 1 ). Under REACH, the set information requirements escalate by tonnage produced or imported ( Table 2) . Waiving of testing is only possible for specific endpoints and only if a similar level of safety can be achieved. This can either be by means of justified computational calculations, read-across or grouping (Table 1) .
Testing for skin corrosion or skin irritation, as well as skin sensitisation, is already required for the lowest tonnage band. The REACH regulation explicitly states that new tests for these endpoints must be performed in vitro. Only if this fails to provide adequate data, in vivo testing is to be considered. Similarly, for substances registered at ≥10 tonnes per year, in vivo testing shall be considered only if results obtained in chemico or in vitro are inconclusive. In addition, dermal acute toxicity has to be tested under certain conditions where there is sufficiently high potential for skin exposure and absorption (Table 2) . Tonnage levels above 100 or 1000 tonnes per year then require increasingly elaborate safety testing, the data of which can be used to address systemic effects after dermal exposure.
The BPR has similar information requirements. However, unlike REACH, the BPR distinguishes between core data and additional data. The core data comprise studies on skin corrosion and irritation as well as sensitisation. While for the first two the BPR refers to REACH, the assessment of the latter requires a systematic review of all available human, animal and alternative data. This is then to be followed by a murine local lymph node assay (LLNA, OECD TGs 429, 442A, 442B; Table 1 ) unless there is clear evidence for classification as skin sensitiser or corrosive agent. Additional toxicity testing in vivo usually is required but, similarly to REACH, will rely on dermal exposure only if the substance has a sufficiently high potential for dermal absorption, oral exposure or inhalation of the substance is unlikely, or skin contact in production and/or use is likely.
It should be noted that in contrast to a full risk assessment, classification under CLP is limited to the determination of the intrinsic hazards of a substance or mixture, thus omitting exposure.
However, similar to the other regulations, the main endpoints relating to skin are skin corrosion and irritation, sensitisation and acute toxicity via the dermal route with new testing only to be performed when all other means of generating information are exhausted. This includes bridging, weight-of-evidence and expert judgement.
In contrast, the European cosmetics regulation explicitly prohibits any toxicity testing in vivo. Yet it requires a toxicity profile for Read-across Using relevant information from analogous substances, for example defined by grouping, to predict the properties of the substance in question. The applicability must be scientifically justified for each substance involved Weight-ofevidence All available information from all possible sources are gathered, including published literature, read-across from chemical analogues, (Q)SAR predictions, data from existing studies, in vitro studies and epidemiological data/human experience. The evidence is weighed by quality of the data, consistency of results, nature and severity of effects, and relevance of the information using scientific judgement
Expert judgement
Weighing of the quality of data by an expert for the examined endpoint Waiving If information by bridging, grouping, read-across or weight-of-evidence is sufficient to replace data of a guideline test, the latter is not performed K P value Permeability coefficient, considered of limited value for evaluating risks. K P describes the steady-state flux divided by the difference in concentrations of donor and acceptor compartments. The product of K P and solubility can be used to estimate the maximum flux through the skin lg K OW Octanol-water partition coefficient. A descriptor for hydrophobicity by determination of the distribution of a substance between water and 1-octanol phases. It is assumed that substances with a very low or a very high lg K OW poorly permeate skin. In the former case the hydrophilic substance does not enter the skin; in the latter case the lipophilic substance does not cross the stratum corneum
TA B L E 2 REACH information requirements for human health (requirements pertaining to physicochemical data and ecotoxicological information are not listed for brevity and are available in the guidance on registration, chapter 4. 
| TE S TING -S PANNING THE S K IN
The above endpoint listings for dermal toxicity put a strong focus on the barrier and immune functions as these are usually the first functions to be affected by chemical exposure. Further toxicologically relevant aspects of skin include its presystemic first pass metabolism; allergen triggered excitation and its capacity for self-renewal.
Moreover, the skin hosts our second largest microbiome with its plethora of reciprocal host-microbe interactions that shape our immunology as well as our metabolism. [2, 3] 
| Skin corrosivity and skin irritation
Given the aforementioned complexity, any model system, be it animal or in vitro, can only be partially representative for the human situation. This already becomes apparent even for biologically less complex endpoints such as skin irritation and corrosion. The first is by definition reversible and hence classified as a hazard of potentially less concern, that is category 2, under CLP. In contrast, necrotic skin corrosion constitutes an irreversible category 1 damage.
Concern may also arise in case of non-irritant induced dryness, flaking or cracking of the skin. Respective testing has traditionally relied on the Draize skin corrosion test (OECD TG 404). [4] The test scores signs of substance-induced irritation and corrosion on live rabbits.
Adopted in 1981, the test belongs to the early OECD test guidelines (TGs, Table 1 ) and as such has produced a large, albeit mostly proprietary database. However, its predictive value for irritants has been questioned and experimental animals might experience severe pain and distress during the procedure. [5, 6] Therefore, efforts for an adequate replacement started early on, resulting in several TGs.
The commercially available CORROSITEX ® system relies on an in pH in the range of 4.5-8.5. [7] Another alternative is the use of skin explants from sacrificed animals. The transcutaneous electrical resistance (TER) test uses such explants from rat to distinguish between corrosive and non-corrosive chemicals (OECD TG 430). [8] Test materials are applied for up to 24 hours, and loss of stratum corneum integrity and barrier function is measured as a reduction in TER using a Wheatstone bridge. The test was shown to be predictive of corrosivity in the Draize rabbit test and yields conservative results when compared to human patch testing. [9] However, unlike the CORROSITEX ® system, it does not allow reliable subcategorisation (Table 3) . Also, there are differences in the assays performance when comparing rat skin to human skin. [10] Other tests such as OECD TG 431 rely on reconstructed human epidermis (RhE) for the identification of corrosive chemicals. The
EpiSkin™ RhE is generated from adult human-derived epidermal keratinocytes cultured on a collagen type IV-coated collagen type I matrix. [11] The test chemical is applied topically for up to four hours, followed by subsequent assessment of cytotoxicity by an MTT assay. [12] Again the method is limited in terms of subcategorisation but can reliably distinguish the most severe category 1A from subcategories 1B/1C (Table 3) . Three other RhE models have been validated as sufficiently similar with regard to their performance. These are the EpiDerm™, [13] the SkinEthic™ [14] and the epiCS ® . [15] Besides their use for assessing corrosivity, RhE models are also used for skin irritation testing (SIT). In contrast to the corrosive barrier breakdown, skin irritation describes a process by which a series of events, from the penetration of the chemicals through the stratum corneum to inflammation of underlying keratinocytes and other skin cells, eventually leads to erythema and oedema due to dilation and increased permeability of endothelial cells. [16] There are four RhE models accepted under OECD TG 439, namely EpiSkin™, [11] EpiDerm™ SIT (aka EPI-200), [13] SkinEthic™ [14] and LabCyte EPI-MODEL24 SIT. [17] Of these, the SkinEthic™ has been adapted also for the testing of finished cosmetic products. [14, 18] Test materials are usually applied topically for 15 to 60 minutes. Subsequent processing is similar to OECD TG 431 but adds a post-treatment period of usually 42 hours before measuring viability using MTT. [16] While all assays allow reliable categorisation as irritant, it should be noted that the long posttreatment makes corrosivity testing a prerequisite.
More RhE systems are being developed, for instance KeraSkin-VM, [19] China EpiSkin, [20] USP-RHE [21] and from hairfollicle-derived keratinocytes, [22] in part to avoid costly commercial kits. As systemic approach, epithelial models have many advantages, including their metabolic competence. However, they are limited by their fragility and tendency of drying. Furthermore, detachment of cells can lead to misinterpretation of data and as current systems only emulate the epithelial layer possible effects of substances that penetrate the stroma and endothelium cannot be detected. [23, 24] Also, neither the reversibility of irritation nor systemic effects including hormone, immune and neural influences can be assessed with these models. Nonetheless, skin corrosion and irritation are the endpoints with the most advanced set of regulatory accepted in vitro methods available and have thus been the first to be casted into a standardised integrated approach to testing and assessment (IATA, Table 1 ).
[25]
Moreover, most of the remaining issues are likely to be solved with the addition and refinement of new biomarkers. For example, while for skin irritants the MTT has so far been the method of choice, a validation study employing five different models showed that relying on cytotoxicity alone has its limitations as it does not always produce the right prediction. [26] [27] [28] This can be addressed by adding additional read-outs such as cytokines. [16, 29] Potential candidates include IL-1α which is a crucial trigger for inflammation in the skin. As sensory mediator, IL-1α induces the production of proinflammatory cytokines IL-6 and IL-8 as well as IL-1α in keratinocytes. [30] [31] [32] Likewise, the IL-1 receptor antagonist (IL-1ra) has been suggested as a suitable predictor for differentiating mild and strong irritating surfactants. [33] Clinical studies showed the ratio of IL-1ra
to IL-1α to be a good predictor of skin inflammation. [34] In addition, tumour necrosis factor-alpha (TNFα) and the chemokines CCL20, CCL27, together with CXCL8 were found to be induced after irritant exposure. [35] Another potential marker is the release of skin-derived anti-leukoprotease SKALP/elafin. [36, 37] 
| Skin sensitisation
Likewise, skin sensitisation can be described by defined molecular key events and has thus been cast into a so-called adverse outcome pathway (AOP; Table 1 ). The AOP for skin sensitisation was the first to be defined from the molecular initiating event to the adverse effect, namely allergic contact dermatitis.
[38] The first key event is the cova- to three studies should then lead to correct classification according to potency for sensitisation. There are several validated methods available for such an iterative approach which is even accessible to machine learning. [39] The only limitation is the lack of distinction between sensitising categories 1A and 1B. While it is questionable if this really serves public health rather than regulatory convenience, the ongoing discussions surrounding this issue perfectly illustrate the difficulties that arise if one tries to adapt the science without considering adequate adjustments to the framework.
In terms of methods, the first key event is addressed by the direct peptide reactivity assay (DPRA, OECD TG 442C). The assay measures test substance reaction with nucleophilic moieties of synthetic peptides, namely the amino group of lysine and the sulphhydryl group of cysteine. [40] As a true in chemico assay, the DPRA currently fails to detect pro-and prehaptens, that is molecules that need metabolic or non-enzymatic activation. Current work on further development of the DPRA thus concentrates on the addition of activating supplements such as peroxidase or hydrogen peroxide. [41, 42] Another issue is the assays incompatibility with metal-containing compounds.
The second key event is emulated by the ARE-Nrf2 luciferase test (KeratinoSens™, OECD TG 442D), which assesses activation of the antioxidant response element (ARE) in keratinocytes. [43, 44] Activation of the ARE usually follows the dissociation of the transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2) that in turn follows the dissociation of the sensory Kelch-like ECHassociated protein 1 (Keap1). [45] The latter senses the cellular oxidation state employing a cysteine residue, which may also be affected by electrophiles such as some sensitisers. [44] The KeratinoSens™ assay exploits this by means of an ARE-dependent luciferase reporter system stably introduced into HaCaT cells. Other similar assays such as the LuSense are under development. [46] The advantage of luciferase-based reporter assays is their sensitivity and ease of use. What is more, interference is rare and usually restricted to direct structural interactions of test substance with the luciferase enzyme. [47] Assessment of the third key event remains challenging due to the and CD54 are thought of as mimicking DC activation. Following substance exposure, the assay uses flow cytometry to quantify respective surface marker expression to discern between sensitisers and non-sensitisers. [48, 49] A similar assay, the myeloid U937 skin sensitisation test (U-SENS™), is currently also at draft stage at the OECD. Here, CD86 expression is measured after treatment of the human histiocytic lymphoma cell line U937. [50, 51] Concomitantly, an interleukin-8 reporter gene assay (IL-8 Luc assay) has also been developed and too is in preparation to become an OECD TG. [52] The [53] the Buehler test [54] (OECD TG 406) and the LLNA. For the guinea pig tests, an initial exposure is followed by a challenge of the highest non-irritant dose 10-14 days later. Skin reactions are visually assessed and graded subjectively.
In comparison, the LLNA clearly is more advanced as its testing procedure not only reduces the number of animals used and pain and distress suffered but it also relies on a measurable endpoint instead. Proliferation of lymphocytes is measured using either radioactive (TG 429) [55] or fluorescent (TG 442B) DNA marker incorporation [56] or by measurement of ATP content (TG 442A). [57] Although generally highly reliable, the assay can suffer shortcomings for metals, some surfactant-type substances or certain functional groups. [58, 59] Despite the aforementioned limitations, skin sensitisation is amongst the most developed endpoints ready for a fully non-animal IATA. Correspondingly, a selection of 12 case studies has been described, as have suitable classification trees based on DPRA, KeratinoSens™, h-CLAT and in silico predictions.
[60,61]
| Acute dermal toxicity
Testing for acute dermal toxicity usually only is required when the more sensitive routes of oral and inhalation exposure have been ruled out and only after dermal penetration has been confirmed. Yet, the only two available guidelines are in vivo tests. These are OECD TG 402 in which a classical lethal dose is to be established or the more recent OECD TG 434 which advises to stop testing when toxicity is evident or latest when the first mortality occurs. According to signs of toxicity, GHS categories 1 (severe)-4 (harmful) are then assigned to the test material. Unlike for other endpoints, significant progress towards non-animal acute dermal toxicity testing is lacking, partly because of its systemic complexity but also because this endpoint has been under the least pressure to do so. [62, 63] 
| Skin absorption
Information on skin absorption is important to extrapolate systemic toxicity or in vitro cytotoxicity to acute dermal toxicity. [64] Moreover, by demonstrating that a substance is not absorbed or does not penetrate skin, certain testing requirements such as acute dermal toxicity can be waived. Absorption data can be generated using two TGs.
The first OECD TG 427 is an in vivo assay in which the labelled test material is applied to at least 10 cm 2 of clipped rat skin. After the animal is sacrificed, body fluids are collected and the treated skin is tape-stripped and the corresponding compartments are analysed for substance deposition. Alternatively, OECD TG 428 uses excised skin in a diffusion cell. Principally applicable, the method still experiences issues regarding parameter definition and substance-specific validation. [65] In addition to the variation between different sources of skin and the acceptor fluid, homogeneous application of the test material, seals and stirring speed amongst others can be critical parameters for reproducibility. [66, 67] 
| Photo-induced toxicity
Phototoxicity is the sunlight-induced or sunlight-enhanced toxic effect of a test material applied topically or systemically. As a lightinduced process, phototoxicity depends on the potential for light absorption and substances with molar extinction coefficients of less than 10 L × mol −1 × cm −1 are hence excluded from testing. For the other candidates, the OECD guideline pool provides TG 432. This in vitro test employs mouse embryonal BALB/c 3T3 fibroblasts and neutral red staining to assess cytotoxicity in the presence or absence of sunlight, respectively. [68, 69] Despite much critique of its limitations, [70] [71] [72] OECD TG 432 is considered robust. Nonetheless, the use of RhE has also been explored, albeit with less success. [73] [74] [75] 
| E XPEC TATI ON S-CURRENT AND FUTURE DE VELOPMENTS
Regulatory toxicology has to warrant the safety of hundreds of millions of people without the comfort of clinical trials. Given that the existing toxicological tests seem to have served us not too badly, it therefore comes as little surprise that any proposed change or amendment to safety testing tends to be greeted with scepticism. This is helpful if it serves the development of better tests. At times, it also leads astray though, especially when focussing on perceived rather than real limitations of alternative approaches or if one omits to see the limitations of animal models, for that matter. Rat skin, for example, has a higher permeability and different metabolism than human skin. [76] Yet, most in vitro models currently employed under the OECD TG programme indeed suffer from three inherent drawbacks. These are the frequent lack of sufficient metabolic capacity, the limited set of cell types employed by these models (often only one) and lastly the requirement for test materials to be soluble in aqueous buffers or cell culture media.
The use of ex vivo skin tissue or surrogates thereof would do away with most of these drawbacks although topical application of test material still is associated with model specific challenges. [67] Moreover, while arguably the best model is excised human full skin from mastectomies and abdominoplastic surgeries supply of primary material is limited as is reproducibility due to donor variation. [77] Also, freezing for transport and storage irreversibly alters the skin's properties. [78, 79] Biologically, pig skin could be an alternative as it features similar barrier properties to human skin. [80, 81] However, any extended use for toxicity testing still requires more development and test system validation.
In terms of ready applicability, further development of the existing RhE-technology therefore has the biggest potential. Fullthickness (FT) models that include fibroblasts such as EpiDerm-FT [82] and Phenion-FT [83] are available. [24] More cell types can be included such as melanocytes [84] and dendritic cells. [85] Moreover, dermoepidermal human skin equivalents with vascularisation using four different cell types in a sandwich fabrication process show promising results. [86, 87] Lessons may also be learned from tissue construction by 3D-printing which can be applied to construction of FT-skin models on scaffolds. [88] [89] [90] [91] [92] Current RhE are produced from primary human keratinocytes, but it is also possible to employ cell lines such as HaCaT [93, 94] and others. [95] Successful use of cell lines would not only drastically decrease cost but improve reproducibility. Employing models derived from different cell lines in parallel could also improve representativeness by covering natural variation. Finally, while transformed cells are limited in their comparability to primary cells, they might still prove sufficient for certain testing purposes.
Given that models prepared from primary human cells can be assumed to exhibit close-to-normal cell cycle control, DNA repair and feature functional though decreased levels of phase I and phase II metabolism, [96] [97] [98] they should actually be well suited for genotoxicity testing in vitro, omitting the need for an exogenous rodent enzyme mix. [99, 100] The micronucleus test (OECD TG 474 and 487) [101] and the comet assay (OECD TG 489) [102] are two tests for genotoxicity that can be used on tissue as well as cultured cells and that are currently explored for use with RhE. [103] [104] [105] [106] [107] The general metabolic competence of FT-models has previously been demonstrated with benzo[a]pyrene as the archetypic phase I-dependent procarcinogen. [108] Moreover, such models will also allow emulating the influence of the microbiome and its metabolism on skin toxicity, [24, [109] [110] [111] Having said that, it has to be noted that more complex does not necessarily mean better. Simple assays such as the NRU phototoxicity test do have their charm. Such assays are usually fast, inexpensive and can often easily be adapted to high-throughput strategies. Dye-based read-outs for cytotoxicity can be replaced by label-free cell impedancebased methods if necessary. [112, 113] Cell culture plates that include electric sensors also offer the possibility of adding additional read-outs such as pH or pO 2 . [114] Artificial membranes such as the skin-parallel artificial membrane permeability assay (skin-PAMPA) and Strat-M™ can be used to determine Kp values (Table 1 ) in order to prioritise or rank compounds for further testing. [115] [116] [117] [118] Likewise, adding biomarkers to existing assays can help to improve their predictivity. Skin sensitisation for instance may be assessed using models that include monocytederived dendritic cells or Langerhans cells and biomarkers such as programmed death-ligand 1 (PD-L1), DC immunoreceptor (DCIR), NAP-2, IL-16, IL-8 and MIP-1α as suitable read-outs. [119] Finally, there has been huge progress in modelling and grouping of substances and their effects. Mathematical algorithms describing epithelial transport and also (quantitative) structure-activity relationship ((Q)SAR) models for skin irritation, corrosion and sensitisation have been explored for a long time. [120, 121] (Q)SAR models are mostly developed for small datasets of specific groups of compounds, defining a limited applicability domain. Parameters usually employed in the development of (Q)SAR algorithms are lipid solubility, aqueous solubility, lg K OW (Table 1) , vapour pressure, melting point, pH, surface tension and molecular weight. Moreover, for skin sensitisation, protein/ electrophilic reactivity and the presence of alert chemical groups are important parameters. Once collected, these parameters are then fed into hypothesis-driven models. Corrosion for example is predominantly considered a physical effect and is usually modelled based on the relative uptake of compounds within a group of potentially corrosive compounds, such as phenols and acids. [122] Irritation modelling on the other hand is derived from the reactivity of solutes with macromolecules in the viable epidermis and dermis. [123, 124] For both processes, a total of more than 20 models are currently available. [125] (Q)SAR models for skin sensitisation are either based on chemical class or mechanism, or are derived empirically using statistical approaches. [126, 127] Modelling of dermal absorption of chemicals has recently been improved by modelling the transport and disposition kinetics of chemical compounds in multilayered skin at the cellular level. [128, 129] Molecular dynamics simulation of chemical binding to keratin at the subcellular level can be used to model transport and disposition properties of epithelia. [130] This represents significant improvement to earlier permeability models that were not acceptable from a regulatory point of view.
[131] With such tremendous progress, it is understandable that modelling is at times proclaimed as the all-inclusive solution for alternative testing. Yet, the quality and versatility of (Q)SARs depend on the empirical data used to develop them. Hence, they strongly rely and profit from further investigation into the underlying biophysical and biochemical mechanisms of toxicity and the validity/applicability of the corresponding data.
Finally, the current regulatory system is prone to assay bias. First, the evaluation of assay applicability is often inherently influenced by the question of how well an assay will fit into the existing system/legal framework. While this is well understandable from a point of practical convenience, this should not be an argument against tests or testing strategies which are otherwise scientifically sound. Examples for this F I G U R E 1 OECD testing guidelines (TGs) that use alternative approaches. A schematic section of the skin is shown with the different OECD TG numbers associated with the part of the skin they simulate are the ongoing and often tedious discussions about the applicability of testing alternatives for skin corrosion or sensitisation. Second, any assay aiming for regulatory application and acceptance has to be validated. However, validation often still refers to data from animal tests as gold standard. In doing so, one has to be aware that many in vivo assays have never been systematically assessed for their performance/predictivity. This should be changed, for currently, this not only prohibits unbiased assay validation but possibly also improved testing.
| CON CLUS ION
The large number of in vitro methods adapted as OECD TGs in the last fifteen years (Figure 1 ) has changed the regulatory landscape tremendously and with omics and microphysiological organ systems already well above the horizon new further improved test systems are sure to come. [24, 132, 133] And while no single model can represent the complexity of the human body, aligning the different methods in IATAs can improve the overall predictive power, even though IATAs may be viewed critically. [134] Another crucial factor for regulatory relevance is the validation of the various models and methods. This applies to the need to streamline and optimise the time needed for validation as well as the fact that validation depends on the quality and relevance of the reference data used for it. A similar statement holds for in silico approaches, and these can only be as good and relevant as the data they are based on.
While the push for non-animal testing laid down in European legislation and particularly in the European cosmetics regulation has brought animal-free regulatory testing one step closer, it will take more efforts to take it the whole way. This applies to the need for improving and developing suitable test systems as well as to the willingness to continuously scrutinise and adapt the regulatory framework and assay validation to new science and its pace. The reward for doing so is not only better testing but improved health protection.
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